Welcome to our dedicated page for Evolent Health news (Ticker: EVH), a resource for investors and traders seeking the latest updates and insights on Evolent Health stock.
Evolent Health, Inc. (NYSE: EVH) regularly issues news and updates that reflect its focus on better health outcomes for people with complex conditions and on specialty care solutions for payers and providers. Company news often highlights developments in oncology and other complex specialties, financial performance, strategic transactions and leadership changes.
Investors and industry observers following EVH news can expect recurring coverage of quarterly and annual financial results, including revenue and adjusted EBITDA metrics and management commentary on demand for complex specialty care solutions. Evolent frequently reaffirms or updates its financial guidance through press releases and related 8-K filings, and schedules conference calls and webcasts to discuss these results.
Evolent’s news flow also features clinical and partnership initiatives. For example, the company has announced a national partnership with American Oncology Network to introduce a model for cancer care that seeks to improve quality and affordability while reducing reliance on prior authorization. This model incorporates quality initiatives, AI-driven clinical insights through the MiBA analytics platform, payment innovation, and care navigation programs that use a cancer care management platform to support patients.
Corporate and capital markets announcements form another key part of EVH news. Recent items include the pricing and issuance of 4.50% convertible senior notes due 2031, repurchases of existing convertible notes and Class A common stock, and amendments to credit agreements and commitment letters for incremental financing facilities. Evolent also publishes updates on strategic portfolio actions, such as the divestiture of its value-based primary care business, Evolent Care Partners, to Privia Health Group, Inc.
Governance and leadership updates appear in the news as well, including appointments to executive roles, changes in the Chief Financial Officer position, and board retirements and appointments. For readers tracking EVH, this news page offers an ongoing view into how the company communicates its financial performance, specialty care initiatives, capital structure decisions and organizational evolution.
Evolent Health, Inc. (EVH) reported Q2 2022 revenue of $319.9 million, a 44.1% increase year-over-year. The net loss was $4.6 million, improving from a $9.1 million loss in Q2 2021. Adjusted EBITDA reached $21.7 million, reflecting a margin of 6.8%. The company added 10 new operating partnerships in 2022, exceeding its goal. Total Lives on Platform reached 21.9 million. For Q3, revenue guidance is set between $343.0 million and $363.0 million. Full-year revenue is projected to be $1.32 billion to $1.36 billion.
Summary not available.
Evolent Health (NYSE: EVH) will report its second quarter 2022 operating results on August 2, 2022, post-market. A conference call is scheduled at 5:00 p.m. Eastern Time where interested parties can join by calling 855.940.9467 or 412.317.6034. An audio replay will be accessible on the company’s investor relations website for 90 days. Evolent Health is known for its clinical and administrative solutions aimed at improving health care affordability and efficiency, and serves a national client base among leading payers and providers.
Evolent Health has announced a definitive agreement to acquire IPG, a provider of surgical management solutions for musculoskeletal conditions, for $375 million plus up to $87 million in contingent consideration. The acquisition aims to enhance Evolent's position in value-based specialty care and is expected to be immediately accretive to Adjusted EBITDA margins and cash flow. The integration will diversify Evolent’s customer mix and provide valuable relationships with national commercial health plans.
Evolent Health, Inc. (NYSE: EVH) has announced that its CEO Seth Blackley, CFO John Johnson, and VP of Investor Relations Seth Frank will participate in several investor conferences in May and June 2022. The events include presentations at the BofA Securities Health Care Conference on May 12, RBC Capital Markets Global Healthcare Conference on May 17, and the 42nd Annual Growth Stock Conference on June 6. Additionally, Johnson and Frank will attend the J.P. Morgan Healthcare Services Summit on June 21, which will not be webcasted. Live webcasts will be available on the company's Investor Relations website.
Evolent Health, Inc. (NYSE: EVH) reported Q1 2022 revenues of $297.1 million, up 38.1% YoY, with net losses of $5.4 million. Adjusted EBITDA reached $24.3 million, yielding an 8.2% margin. Total lives on the platform stood at 20.3 million. The company announced new partnerships, including AvMed's expansion into oncology services and Bright Healthcare's member increase for 2023. For Q2 2022, revenue guidance is set at $290.0 million to $305.0 million, while full-year revenue is projected between $1.16 billion and $1.21 billion.
Evolent Health (NYSE: EVH) will announce its first quarter 2022 operating results on May 4, 2022, after the market closes. A conference call will follow at 5:00 p.m. Eastern Time. Interested shareholders can access the live broadcast by calling 855.940.9467 or 412.317.6034 (international). An audio playback will be available for 30 days on the company's investor relations website. Evolent Health provides clinical and administrative solutions to enhance healthcare delivery, serving a national network of leading payers and providers.
New Century Health (NCH) reported that its partner, Cancer Care Specialists (CCSI) of Illinois, earned nearly
Evolent Health, Inc. (NYSE: EVH) announced participation in two upcoming investor conferences. Chief Financial Officer John Johnson and Vice President of Investor Relations Seth Frank will present at the 42nd Annual Cowen Health Care Conference on March 7, 2022, at 9:10 a.m. ET, and at the KeyBanc Life Sciences & MedTech Investor Forum on March 22, 2022, at 9:00 a.m. ET. Live audio webcasts will be available on Evolent's investor relations website, with replays accessible shortly after the events.
Evolent Health (NYSE: EVH) reported Q4 and full-year financial results for 2021, showcasing GAAP revenue of $248.4 million, a slight increase of 0.7% year-over-year. In contrast, full-year revenue fell by 1.8% to $908.0 million. Notably, revenue excluding divested assets grew by 39.7% and 36.7% for Q4 and the full year, respectively. Despite a net loss of $(5.6) million in Q4 and $(37.6) million for 2021, Evolent achieved an Adjusted EBITDA of $24.3 million for Q4 and $66.3 million for the year. The company also announced new partnerships, enhancing its service delivery.